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Introduction: In a previous report, we demonstrated a favorable trend for supplementation with antithrombin (AT)
concentrate at a dosage of 3,000 IU/day over 1,500 IU/day for the treatment of sepsis-associated disseminated
intravascular coagulation (DIC) in patients with an AT activity of 70% or less. Since the survival difference did not
reach statistical significance, we planned to examine the effects in a larger number of cases with severer disease.
Methods: We performed a non-randomized multi-institutional survey. In total, 307 septic DIC patients who had AT
activity less than 40% and who had undergone AT substitution at a dose of either 1,500 IU/day or 3,000 IU/day for
three consecutive days were analyzed. Of these, 259 patients received 1,500 IU/day (AT1500 group) and 48 patients
received 3,000 IU/day (AT3000 group). The primary efficacy endpoints were recovery from DIC by day 7 and an all-cause
mortality on day 28. Adverse bleeding events were also examined. A logistic regression analysis was conducted by
using age, sex, body weight, initial AT activity, DIC score, platelet count, coadministration of heparin, recombinant
thrombomodulin, suspected source of infection, surgery, and supplemented AT dose.
Results: Supplementation significantly decreased the DIC score in the AT3000 group, leading to the superior resolution
of DIC, compared with the results in the AT1500 group (66.7% versus 45.2%, P = 0.007). In addition, the AT3000 group
exhibited a better survival than the AT1500 group (77.1% versus 56.4%, P = 0.010). Bleeding events were observed in
6.96% (severe bleeding: 3.04%) in the AT1500 group and 6.52% (severe bleeding, 4.35%) in the AT3000 group
(P = 1.000; severe bleeding, P = 0.648). A logistic regression analysis revealed that the use of AT3000 (odds ratio (OR),
2.419; P = 0.025), a higher initial platelet count (OR, 1.054; P = 0.027), and patient age (OR, 0.977; P = 0.045) were
significantly correlated with an improved survival.
Conclusions: The AT3000 group exhibited significantly improved rates of survival and recovery from DIC without an
increased risk of bleeding, compared with the AT1500 group, among the patients with sepsis-associated DIC and an AT
activity of less than 40%.Introduction
Severe sepsis is almost consistently associated with a
hyper-coagulatory status [1] and frequently leads to dis-
seminated intravascular coagulation (DIC) [2]. Excess
clot formation, leading to malcirculation in organs and
subsequent organ failure, is driven by activated coagula-
tion, by impaired anticoagulant mechanisms, including
the antithrombin (AT) and protein C system, and by the* Correspondence: toshiiba@cf6.so-net.ne.jp
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unless otherwise stated.depression of the fibrinolytic system [3]. Thus, supple-
mentation with AT concentrates has been considered a
rational therapy [4].
Previously, the results of a large-scale randomized con-
trolled trial (RCT) known as KyberSept, which examined
the effects and adverse events of high-dose AT for the
treatment of severe sepsis, were published [5]. This trial
demonstrated that AT did not provide survival benefit
and instead increased the risk of bleeding. Since AT, par-
ticularly when administered with heparin, increases the
risk of bleeding significantly, the international guidelines
for severe sepsis recommend “not to use high-dose AT
for severe sepsis” [6]. Since the completion of KyberSept,. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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systematic review of AT use in patients with DIC with
severe sepsis concluded that AT might increase the over-
all survival [7]. Furthermore, Fourrier [8] demonstrated
an improvement in all-cause mortality across subgroups
defined according to the DIC status at entry in RCTs
of AT and activated protein C. Therefore, it may be
too early to conclude that AT is not effective for sepsis-
associated DIC.
Recently, the Japanese Association for Acute Medicine
(JAAM) DIC study group performed a prospective RCT
and reported that 30 IU/kg per day of AT could decrease
the DIC score, compared with a placebo, in septic DIC
patients with a baseline AT activity level of between 50%
and 80%, which subsequently resulted in an increase in
the DIC resolution rate [9]. Unlike high-dose adminis-
tration, the supplementation of AT, in which the recov-
ery of AT activity to within the normal range is targeted,
has been thought to be beneficial in patients with septic
DIC in Japan [10,11]. As a result, AT supplementation was
included in the Japanese guidelines for sepsis-associated
DIC [12]. However, a lack of sufficient evidence has also
been pointed out [13]. Under these circumstances, the re-
cent international guideline for the management of DIC
has also recommended the use of AT in situations in
which the efficacy of such treatment has been proven [13].
Therefore, the examination of the effects and the adverse
events associated with this therapy has become an urgent
matter.
In a former study, we examined a total of 729 sepsis-
associated DIC patients with AT activity levels of 70% or
lower and reported that 3,000 IU/day of AT substitution
for 3 days (AT3000) was a significant factor associated with
an improvement in survival, compared with 1,500 IU/day
of AT substitution (AT1500) (odds ratio (OR) 1.912;
P = 0.026). However, the survival difference between
AT3000 and AT1500 was not statistically significant when
examined by using a Fisher’s exact test [14]. The other
finding in our study was that AT3000 was more effective
in a patient population with a lower baseline AT activity.
Thus, we further accumulated septic DIC patients with a
baseline AT activity of less than 40%. The primary goal of
the present study was to confirm an improvement in the
resolution of DIC by day 7 and a reduction in all-cause
mortality on day 28.
Materials and methods
Definitions
Both systemic inflammatory response syndrome (SIRS)
and sepsis were defined according to the definition of the
American College of Chest Physicians/Society of Critical
Care Medicine consensus conference [15]. The severity of
the illness of the patients was evaluated according to the
AT activity [16], JAAM DIC score [17], and Sepsis-RelatedOrgan Failure Assessment (SOFA) score at the time of
enrollment. DIC was defined on the basis of the JAAM
DIC criteria [18], and the DIC scores were calculated by
using this system. The scoring system consists of the SIRS
score, platelet count, fibrin/fibrinogen degradation prod-
uct (FDP), or D-dimer and prothrombin time ratio; these
values were measured in local laboratories. Organ failure
was assessed by using the SOFA score [19]. Bleeding
events were recorded for 28 days. Bleeding was classified
as major if it was intracranial or required a transfusion of
at least 3 units of blood. Less-severe bleeding was defined
as minor bleeding [5].
Patient selection and data collection
This survey was performed as a non-randomized, multi-
institutional, post-marketing survey. In total, 307 sepsis-
associated DIC patients with an AT activity of less than
40% who were treated in 217 hospitals between May 2006
and March 2013 were examined in this study. Patients
with a history of allergic shock reaction to AT were ex-
cluded. The study was conducted in accordance with the
Declaration of Helsinki and Good Post-marketing Surveil-
lance Practice (Good Vigilance Practice and Good Post-
marketing Study Practice). The institutional review boards
that approved this study can be found in the Acknowledg-
ments section. The patients’ agreement and consent were
obtained when required by the ethics committee of each
hospital (between May 2006 and September 2009). All ne-
cessary informed consent was obtained from the patients
or their relatives by the physician in charge. From Septem-
ber 2009, the agreement was waived since the Japanese
Ministry of Health, Labor and Welfare judged that the pa-
tients’ agreement was not necessary. Patients were regis-
tered by the patient registration center, and serial data
regarding the AT activity, SIRS score, coagulation markers,
and DIC scores were obtained on the day before AT ad-
ministration (day 0) and on days 2, 4, and 7 after AT ad-
ministration. DIC was judged to have been resolved when
the DIC score had decreased to less than 4 as of day 7.
Survival was recorded on day 28. The total bleeding
events, including both major and minor bleeding events,
were recorded throughout the observation period. Scoring
was performed at each hospital.
Either 1,500 IU/day (AT1500) or 3,000 IU/day (AT3000)
of AT concentrate (Nihon Pharmaceutical Co. Ltd., Tokyo,
Japan) was administered for 3 consecutive days when the
patients met the JAAM DIC criteria and had an AT activ-
ity level of less than 40%. AT activity was measured at the
time of the diagnosis of DIC. The use of AT3000 is ap-
proved only for obstetric or surgical DIC patients, and
dose adjustment was permitted, depending on the severity.
However, since no further details were defined, each doctor
decided the dosage on an individual case basis. Standard
sepsis care was performed, and platelet concentrate and
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necessary, as per the guidelines established by the Japanese
Ministry of Health, Labor and Welfare.Laboratory measurements
Platelet count, coagulation, and fibrinolytic markers were
prospectively assessed. When several sets of data were
available on a single day, the least favorable measurement
value was used for the analysis. The methods that were
used to measure platelet count and coagulation included
platelet counting (electric impedance method), prothrom-
bin time (scattered light detection), FDP (latex immuno-
assay), and D-dimer (latex immunoassay). To measure the
AT activity, the plasma anti-Factor Xa activity or the anti-
thrombin activity measured in the presence of 0.22 M
NaCl, excluding the influence of heparin cofactor II activ-
ity, was assessed (chromogenic substrate method, refer-
ence intervals: 70% to 120%). All of the measurements
were performed by local laboratories.Statistical analysis
The paired or unpaired Wilcoxon signed-rank test was
applied for two-group comparisons. The proportions were
compared by using the chi-square test or the Fisher’s exact
test. A Kaplan-Meier curve was calculated, and the sur-
vival difference was examined by using a log-rank test.
The common method of logistic regression analysis (the
enter method) used the outcome (survived, 1; died, 0) as
the criterion variable and the AT variable dose (3000 IU/
day, 1; 1,500 IU/day, 0), patient sex (male, 1; female, 0),
age, body weight, baseline AT activity, baseline DIC score,
baseline platelet count, respiratory tract infection (yes, 1;
no, 0), digestive tract infection (yes, 1; no, 0), urinary tract
infection (yes, 1; no, 0), biliary tract infection (yes, 1; no,
0), other infection (yes, 1; no, 0), unknown infection focus
(yes, 1; no, 0), surgery (yes, 1; no, 0), coadministration of
recombinant thrombomodulin (yes, 1; no, 0), and coad-
ministration of heparins (yes, 1; no, 0) as explanatory vari-
ables. The stepwise method (a forward selection method
based on the likelihood ratio) used 28-day survival as the
criterion variable and patient sex, age, body weight, base-
line AT activity, baseline DIC score, baseline platelet
count, respiratory tract infection, digestive tract infection,
urinary tract infection, biliary tract infection, other infec-
tion, unknown infection focus, surgery and coadministra-
tion of recombinant thrombomodulin, coadministration
of heparins, and the AT variable dose as explanatory vari-
ables. Results were reported as ORs, P values, and 95%
confidence intervals. For all of the reported results, a
P value of less than 0.05 was considered to be statis-
tically significant. The above-mentioned analyses were
performed by using SPSS 13.0 for MAC OSX (SPSS
Inc., Chicago, IL, USA).Results
In total, 307 patients were analyzed in the study. Forty-
eight patients were treated with AT3000 for 3 days, and
259 patients were treated with AT1500 for 3 days. The
mean body weights were 52.3 kg in the AT1500 group
and 52.7 kg in the AT3000 group (P = 0.863).
Table 1 shows the baseline characteristics of the pa-
tients. Respiratory tract infection was the most common
underlying disease in the AT1500 group, and digestive
tract infection was the most frequent in the AT3000 group.
In regard to background differences, digestive tract infec-
tion was more common in the AT3000 group (P <0.01),
and surgery was more common in the AT3000 group
(P <0.01). In regard to disease severity, the JAAM DIC
score, the AT activity, and the SOFA score were identical
between the two groups. The baseline platelet count in
the AT1500 group was 6.0 × 104/mm3 (interquartile range
[IQR] 3.15 to 9.1), which was significantly lower than that
of the AT3000 group (7.9 × 104/mm3, IQR 5.0 to 11.4,
P <0.05). Heparin was used in 24.7% and 16.7% of the pa-
tients in the AT1500 and AT3000 groups, respectively.
Among all of the patients, bleeding events were ob-
served in 19 patients (6.88%), and 9 (3.26%) of these
were classified as severe. Among the severe bleeding cases,
5 occurred in patients with AT substitution without con-
comitant unfractionated heparin administration (2.18%),
and 4 occurred in patients with unfractionated heparin ad-
ministration (8.51%) (P = 0.049). Among the 9 severe bleed-
ing cases, 7 patients (3.04%) were treated with AT1500 and
2 were treated with AT3000 (4.35%); this difference was not
significant (P = 0.648) (Table 2).
Figure 1 shows the changes in AT activities and the
administered AT dose. The AT activities had increased
to within the normal range (>80%) in the AT3000 group,
but this level was not reached in the AT1500 group
throughout the 7 days of observation. As for DIC reso-
lution, AT3000 resulted in a significant reduction in the
DIC score, leading to a better recovery from DIC com-
pared with the AT1500 group (66.7% versus 45.2%, P =
0.007) (Figure 2). A Kaplan-Meier survival curve was cal-
culated by using data obtained for a maximum of 28 days
after the administration of AT. The survival started to de-
crease from day 3 in the AT1500 group and from day 5 in
the AT3000 group, and a significant difference between
the groups was recognized (P = 0.007) (Figure 3). The
AT3000 group exhibited a better survival outcome than
the AT1500 group (77.1% versus 56.4%, P = 0.010 [Fisher’s
exact test], P = 0.007 [log-rank test]).
The enter method of logistic regression analysis showed
that the supplemented AT dose, patient age, and baseline
platelet count were significant factors for survival; that is,
the AT dose (OR 2.419, P = 0.025), patient age (OR 0.977,
P = 0.045), and baseline platelet count (OR 1.054, P = 0.027)
contributed to an improvement in survival. In contrast,








Male 138 (53.3%) 27 (56.3%)
Female 121 (46.7%) 21 (43.8%)
Age in years
14 or under 1 (0.4%) 0 (0.0%)
15-64 60 (23.2%) 13 (27.1%)
65 or over 198 (76.4%) 35 (32.9%)
Suspected source
of infection
Respiratory tract 85 (32.8%) 11 (22.9%)
Digestive tract 78 (30.1%) 25 (52.1%) <0.05
Urinary tract 19 (7.3%) 2 (4.2%)
Biliary tract 28 (10.8%) 4 (8.3%)
Others 26 (10.0%) 6 (12.5%)
Unknown 35 (13.5%) 2 (4.2%)
Surgery 84 (34.0%) 27 (56.3%) <0.05
Baseline AT activity
<30% 88 (34.0%) 19 (39.6%)
30% 171 (66.0%) 29 (60.4%)
SD 31.02 ± 7.25 29.57 ± 8.22
Baseline DIC score
4.5 143 (55.2%) 26 (54.2%)
6 48 (18.5%) 10 (20.8%)
7.8 68 (26.3%) 12 (25.0%)
SD 5.6 ± 1.3 5.7 ± 1.4
Baseline SOFA score
0-6 27 (26.5%) 5 (31.3%)
7-12 46 (45.1%) 9 (56.3%)
13-24 29 (28.4%) 2 (12.5%)
SD 10.1 ± 4.7 7.7 ± 4.3
Median baseline platelet
count, × 104/mm3








Heparin 64 (24.7%) 8 (16.7%)
Thrombomodulin 15 (5.8%) 3 (6.3%)
Values are presented as number (percentage) unless otherwise indicated. AT,
antithrombin; DIC, disseminated intravascular coagulation; FDP, fibrin/fibrinogen
degradation product; IQR, interquartile range; SD, standard deviation; SOFA,
Sepsis-Related Organ Failure Assessment.
Table 2 Bleeding events
Total
Any bleeding Major bleeding
Without concomitant unfractionated
heparin (n = 229)
13 (5.68%) 5 (5.68%)
With concomitant unfractionated
heparin (n = 47)
6 (12.77%) 4 (8.51%)
Total (n = 276) 19 (6.88%) 9 (3.26%)
AT1500 group
Any bleeding Major bleeding
Without concomitant unfractionated
heparin (n = 170)
6 (3.53%) 3 (1.76%)
With concomitant unfractionated
heparin (n = 60)
10 (16.67%) 4 (6.67%)
Total (n = 230) 16 (6.96%) 7 (3.04%)
AT3000 group
Any bleeding Major bleeding
Without concomitant unfractionated
heparin (n = 38)
3 (7.89%) 2 (5.26%)
With concomitant unfractionated
heparin (n = 8)
0 (0.0%) 0 (0.0%)
Total (n = 46) 3 (6.52%) 2 (4.35%)
Values are presented as number (percentage).
Figure 1 Changes in antithrombin (AT) activity. The median
baseline AT activity was less than 40% in both groups. AT activities
increased to the normal range (>80%) in AT3000 group, but this
level was not recovered in the AT1500 group throughout 7 days.
AT1500: 1,500 IU/day of AT substitution for 3 days; AT3000: 3,000 IU/day
of AT substitution for 3 days. The central horizontal bars, columns, and
peripheral horizontal bars indicate the median values, the 25th to 75th
percentiles, and the 10th to 90th percentiles, respectively. *P <0.001
versus AT1500 at each day. #P <0.001 versus AT activity of each group
at day 2, 4, or 7.
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the survival (Table 3). A forward selection method based
on the likelihood ratio of logistic regression analysis
revealed that supplemented AT dose, baseline platelet
count and the coadministratrion of recombinant throm-
bomodulin were significant factors for survival; that is,
Figure 2 Comparison of disseminated intravascular coagulation (DIC) resolution rates. The DIC resolution rates on day 7 were 45.2% in the
group with 1,500 IU/day of antithrombin substitution for 3 days (AT1500 group) and 66.7% in the group with 3,000 IU/day of antithrombin
substitution for 3 days (AT3000 group). The difference in the DIC resolution rates between these two groups was significant (**P = 0.007, Fisher’s
exact test).
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count (OR 1.071, P = 0.002), and recombinant throm-
bomodulin (OR 3.853, P = 0.038) contributed to improved
survival (Table 4).
Discussion
The effectiveness of a supplementation dose of AT for
septic DIC is controversial. Sawamura and colleagues
[20] performed a retrospective analysis in 23 DIC pa-
tients and reported that 60 IU/kg per day of AT did not
show any advantages for the recovery of platelet counts,
coagulation and fibrinolytic markers, and DIC scores,Figure 3 Comparison of survival. A Kaplan-Meier curve was calculated to
of antithrombin and the patients treated with 3,000 IU/day of antithrombin
from day 5 in the in the AT3000 group. A significant difference between thcompared with 30 IU/kg per day of AT. In the current
survey, AT3000 was found to improve the outcome of
sepsis-associated DIC patients significantly, compared
with AT1500. The differences between their study and
ours were not only the numbers of patients but also the
initial AT activity. Since the first survey demonstrated that
the efficacy of AT3000 was more prominent in lower AT
activity, we focused on the patients with AT activities of
less than 40% in the present study.
As for the relationship between the recovered level of
AT activity and efficacy, Gando and colleagues [21] retro-
spectively evaluated the changes in the AT activity aftercompare the survival between the patients treated with 1,500 IU/day
. The survival started to decrease from day 3 in the AT1500 group and
e groups was recognized on day 28 (P = 0.007, log-rank test).
Table 3 Relationship between outcome (28-day survival)




P value 95% confidence
interval
AT dose:
3,000 versus 1,500 IU 2.414 0.025 1.115-5.226
Gender 0.746 0.296 0.432-1.291
Age 0.977 0.045 0.955-0.999
Body weight 0.998 0.901 0.974-1.023
Baseline AT activity 1.004 0.822 0.969-1.041
Baseline DIC score 0.875 0.198 0.714-1.072
Heparin 0.808 0.499 0.435-1.500
Recombinant thrombomodulin 3.639 0.057 0.960-13.790
Baseline platelet count 1.054 0.027 1.006-1.104
Respiratory tract infection 0.632 0.492 0.170-2.343
Digestive tract infection 1.034 0.960 0.279-3.832
Urinary tract infection 3.019 0.140 0.695-13.115
Biliary tract infection 1.208 0.791 0.300-4.871
Other infection 0.799 0.772 0.175-3.640
Unknown infection focus 0.901 0.891 0.203-3.995
Surgery 0.929 0.818 0.498-1.733
AT, antithrombin; DIC, disseminated intravascular coagulation.
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30 IU/kg per day) and reported that patients who achieved
an AT activity level of more than 60% had a better out-
come. In our survey, the AT activity reached over 80% in
the AT3000 group but was around 60% in the AT1500
group. However, whether the recovered AT activity was a
result of the supplementation or the cause of the improve-
ment in survival is not clear. A target activity-oriented AT
supplementation study should be performed to address
this issue.
The main concern regarding the use of AT is the pos-
sible increase in the risk of bleeding. When high-dose AT,
in particular, was administered with either unfractionated
or low-molecular-weight heparin, the number of bleeding
events increased significantly (23.8% for AT with heparinTable 4 Relationship between the outcome (28-day
survival) and various factors using the forward selection




P value 95% confidence
interval
Baseline platelet count 1.071 0.002 1.025-1.119
Recombinant thrombomodulin 3.853 0.039 1.072-13.855
Antithrombin dose
3,000 versus 1,500 IU 2.387 0.020 1.144 -4.983versus 13.5 for placebo; P <0.001) in KyberSept [5]. In
contrast, heparin use did not affect the incidence of bleed-
ing events in our former survey. A total of 193 out of 729
patients (26.5%) received heparin, and neither the inci-
dences of bleeding events (6.55% with heparin versus
6.51% without heparin) nor the increase of serious bleed-
ing events (1.79% with heparin versus 1.68% without hep-
arin) differed between patients treated with and those
treated without heparin. In the present study, the number
of bleeding events was more than two times higher in pa-
tients with concomitant heparin use, compared with those
receiving AT alone. We suspect that the severity of sepsis
and the degree of coagulation disorder might have influ-
enced this difference, but further examination is needed to
clarify this issue. In regard to the bleeding risk without
heparin treatment, the rate was not significantly higher
than that observed in the former survey regardless of the
increase in coagulation disorder. There was no intracranial
hemorrhage and deadly bleeding in this study; however, it
should be kept in mind that the rate of severe bleeding
was doubled in the present study.
Interestingly, the coadministration of recombinant
thrombomodulin was revealed to be another significant
factor for survival by the forward selection method of lo-
gistic regression analysis. Because both AT and thrombo-
modulin activities are known to decrease significantly
during severe sepsis and their mechanisms of action are
independent, a combination therapy could potentially be
beneficial. On the basis of this hypothesis, we examined the
combination effects in the lipopolysaccharide-challenged
animal model and reported that the combination therapy
attenuates organ damage, causes histologic changes, and
leads to an improvement in survival [22,23]. However, the
efficacy has not been proven in the clinical field yet. Fur-
thermore, since the P value did not reach significant in
the enter method, this issue should be discussed in the
next study.
Finally, the present study had several limitations. First,
the superiority of the AT3000 regimen might be related
to the surgery rather than the AT volume. As was shown
by the stepwise logistic regression analysis, surgery was a
significant factor in the use of AT3000, and this result can
be explained by the Japanese health-care system. Since DIC
patients who require surgical treatment and obstetric DIC
patients have lower AT activity levels, the use of AT3000
is approved for these patients. To answer the question of
whether the surgery itself, rather than the AT3000 treat-
ment, might have improved the outcome, it should be
noted that since the enter method of logistic regression
analysis revealed that surgery was not a significant ex-
planatory variable for the outcome, the AT3000 regimen
might be responsible for the improvement in survival. A
second limitation is that the dose allocations were not ran-
domly performed. Although the baseline SOFA score was
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cases (SOFA score >12) was higher in the AT1500 group
than in the AT3000 group (28.4% versus 12.5%), and this
might have affected the results. Third, a placebo control
was not included in the study. Fourth, the patient number
in the AT3000 group was relatively small. In addition, we
cannot eliminate the influence of the higher baseline
platelet count in the AT3000 group. Therefore, we think
that the survey should be continued.
Conclusions
The supplementation of AT at a dose of 3,000 IU/day
(compared with 1,500 IU/day) for 3 days resulted in the
effective modulation of sepsis-associated DIC resolution
and an improvement in the 28-day survival outcome
without increasing the risk of bleeding in DIC patients
with a baseline AT activity level of less than 40%. Although
the results of the present study may provide a rationale
for the use of a supplemental dose of AT, a large-scale
RCT addressing the efficacy and bleeding risk of AT for
DIC in patients with severe sepsis is required.
Key messages
 AT supplementation at 3,000 IU/day improved the
outcome of sepsis-associated DIC in patients with a
baseline AT activity level of less than 40%, compared
with 1,500 IU/day of AT.
 AT supplementation at 3,000 IU/day does not
increase the bleeding risk, compared with AT
supplementation at 1,500 IU/day.
 The concomitant use of heparin may increase the
bleeding risk.
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